Event submissions
Published
This submission belongs to the session C. keynote Presentation of the event 5th International Electronic Conference on Medicinal Chemistry
Published date
01 Nov, 2019
Citation
Leonidas A. A. Phylactou, Use of Aptamers to deliver therapeutic genetic sequences in muscle, in Proceedings of 5th International Electronic Conference on Medicinal Chemistry, 1 November–30 November 2019, MDPI: Basel, Switzerland, doi: 10.3390/ECMC2019-06367
Share
Email
Facebook
Twitter
LinkedIn
Use of Aptamers to deliver therapeutic genetic sequences in muscle
Leonidas A. A. Phylactou 1,2
1. The Cyprus Institute of Neurology and Genetics, Cyprus
2. -
Abstract
There are several types of muscular dystrophy which have as a common characteristic muscle weakness and wasting.
Antisense oligonucleotide approaches hold promise for the development of rational therapeutic approaches against muscular dystrophy.
There is need to improve the delivery of such oligonucleotides in a tissue such as the muscle which is highly abundant in the human body.
During the presentation, I am describing the identification and use of aptamers to enhance delivery in muscle.
Keywords
muscular dystrophy
muscle
antisense oligonucleotides
aptamers
Manuscript
Use of Aptamers to deliver therapeutic genetic sequences in muscle_2019_LAP (002).pdf
Oral Presentation
Use of Aptamers to deliver therapeutic genetic sequences in muscle_2019_LAP (002).pptx
Poster
Use of Aptamers to deliver therapeutic genetic sequences in muscle_2019_LAP (002).pdf
The main products of cyclophosphamide bioactivation exert a cardiotoxic effect at clinical important concentrations in AC16 cardiac cells
Drug (re-)design guided by biophysical characterization of interactions with biomimetic membranes